# Effect of Salovum™ and SPC-Flakes™ on Abemaciclib-induced Gastrointestinal Toxicity in Early Breast Cancer

> **NCT06152471** · PHASE3 · UNKNOWN · sponsor: **Henrik Lindman** · enrollment: 100 (estimated)

## Conditions studied

- Early-stage Breast Cancer
- Diarrhea
- Adverse Drug Event

## Interventions

- **DRUG:** SPC-flakes
- **DRUG:** Salovum
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06152471
- **Lead sponsor:** Henrik Lindman
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-07
- **Primary completion:** 2024-10-31
- **Final completion:** 2025-03-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06152471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06152471, "Effect of Salovum™ and SPC-Flakes™ on Abemaciclib-induced Gastrointestinal Toxicity in Early Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06152471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*